Pharma, Startups

Heart disease startup MyoKardia files for IPO

Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it’s developing small molecule drugs to treat cardiomyopathies.

Bay Area startup MyoKardia, a developer of heart disease drugs, has filed to go public with the SEC. It plans to trade on the Nasdaq under ticker symbol “MYOK.”

The company’s lead candidate, MYK-461, is in Phase 1 trials for hypertrophic cardiomyopathy, which is projected to be complete next year. MyoKardia is taking a precision medicine approach to such heart conditions – studying the underlying genetics and developing small molecule drugs to treat them.

The Third Rock-backed company has raised some $75 million in venture funding since its founding three years ago, including a $46 million Series B this April. Notably, it inked a $245 million deal with Sanofi last year to develop cardiomyopathy drugs.